Thomas Leggett's Insider Trades & SAST Disclosures
Thomas Leggett's most recent trade in Stoke Therapeutics Inc was a trade of 89,000 Employee Stock Option (Right to Buy) done . Disclosure was reported to the exchange on March 20, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Thomas Leggett.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Stoke Therapeutics Inc | Thomas E. Leggett | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Mar 2025 | 89,000 | 89,000 | - | - | Employee Stock Option (Right to Buy) | |
| Stoke Therapeutics Inc | Thomas E. Leggett | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Mar 2025 | 59,000 | 59,000 | - | - | Restricted Stock Units | |
| Stoke Therapeutics Inc | Thomas Leggett | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2024 | 396,200 | 396,200 | - | - | Stock Option (Right to Buy) | |
| Black Diamond Therapeutics... | Thomas Leggett | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2021 | 75,000 | 75,000 | - | - | Stock Option (Right to Buy) | |
| Black Diamond Therapeutics... | Thomas Leggett | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.86 per share. | 08 Jan 2021 | 3,000 | 3,000 (0%) | 0% | 10.9 | 32,580 | Common Stock |
| Black Diamond Therapeutics... | Thomas Leggett | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jan 2021 | 3,000 | 218,171 | - | - | Stock Option (Right to Buy) | |
| Black Diamond Therapeutics... | Thomas Leggett | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 33.94 per share. | 08 Jan 2021 | 3,000 | 0 (0%) | 0% | 33.9 | 101,820 | Common Stock |
| Black Diamond Therapeutics... | Thomas Leggett | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Dec 2020 | 3,000 | 221,171 | - | - | Stock Option (Right to Buy) | |
| Black Diamond Therapeutics... | Thomas Leggett | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.86 per share. | 08 Dec 2020 | 3,000 | 3,000 (0%) | 0% | 10.9 | 32,580 | Common Stock |
| Black Diamond Therapeutics... | Thomas Leggett | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 34.05 per share. | 08 Dec 2020 | 1,941 | 0 (0%) | 0% | 34.1 | 66,094 | Common Stock |
| Black Diamond Therapeutics... | Thomas Leggett | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 33.27 per share. | 08 Dec 2020 | 1,059 | 1,941 (0%) | 0% | 33.3 | 35,233 | Common Stock |
| Black Diamond Therapeutics... | Thomas Leggett | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 32.96 per share. | 09 Nov 2020 | 3,000 | 0 (0%) | 0% | 33.0 | 98,892 | Common Stock |
| Black Diamond Therapeutics... | Thomas Leggett | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Nov 2020 | 3,000 | 224,171 | - | - | Stock Option (Right to Buy) | |
| Black Diamond Therapeutics... | Thomas Leggett | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.86 per share. | 09 Nov 2020 | 3,000 | 3,000 (0%) | 0% | 10.9 | 32,580 | Common Stock |
| Black Diamond Therapeutics... | Thomas Leggett | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Oct 2020 | 3,000 | 227,171 | - | - | Stock Option (Right to Buy) | |
| Black Diamond Therapeutics... | Thomas Leggett | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 33.53 per share. | 08 Oct 2020 | 3,000 | 0 (0%) | 0% | 33.5 | 100,576 | Common Stock |
| Black Diamond Therapeutics... | Thomas Leggett | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.86 per share. | 08 Oct 2020 | 3,000 | 3,000 (0%) | 0% | 10.9 | 32,580 | Common Stock |
| Black Diamond Therapeutics... | Thomas Leggett | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 31.00 per share. | 14 Sep 2020 | 3,000 | 0 (0%) | 0% | 31 | 93,000 | Common Stock |
| Black Diamond Therapeutics... | Thomas Leggett | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Sep 2020 | 3,000 | 230,171 | - | - | Stock Option (Right to Buy) | |
| Black Diamond Therapeutics... | Thomas Leggett | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.86 per share. | 14 Sep 2020 | 3,000 | 3,000 (0%) | 0% | 10.9 | 32,580 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges